Domestic drugs, access to the Chilean procurement market

Korean approved drugs can participate in Chile's procurement market

The KHIDI (Director Deok-cheol Kwon) announced that it has signed a Memorandum of Understanding (MOU) with Chile's Health Procurement Service (CENABAST, Valentin Diaz Gracia, Chief Executive Officer) and Korean companies to advance into public procurement of pharmaceuticals in Chile.

 

The Chilean Health Procurement Authority (CENABAST) manages the public procurement of all medicines and medical devices in Chile and supplies them to public health institutions.

 

Through the signing of this Memorandum of Understanding, the two sides agreed to ▲discover excellent Korean companies that meet procurement needs ▲sign an export contract with the Korean Corporate and CENABAST ▲actively support and cooperate with Korean companies to obtain approval from the Chilean Public Health Service( Instituto de Salud Pública, ISP).

 

In particular, it is said that through this cooperation, products that have not been approved for marketing in Chile can participate in procurement through the preparation of required documents if they have a Korean marketing license.

 

It is said that cooperation with the CENABAST has made it possible to enter the market more quickly.

 

The signing of the Memorandum of Understanding was promoted on the basis of cooperation between the two countries' Ministry of Health (G2G), and the signing of the Memorandum of Understanding between the Ministry of Health and the Republic of Korea in 2015 became an important foundation, the KHIDI said.

 

The Memorandum of Understanding between the Ministry of Health is based on information exchange and joint project cooperation to promote mutual cooperation in areas of common interest, such as health care policy, pharmaceutical and medical device cooperation, and aging.

 

Meanwhile, the KHIDI signed a three-way agreement with the KPBMA (Chairman Hee-mok Won) and the Korea Pharmaceutical Traders Association (Chairman Jang-suk Oh), and plans to cooperate to find companies and derive results to expand the domestic pharmaceutical industry into the Chilean market.

 

To cooperate.

 

It is expected that the agreement will accelerate Korean companies' entry into Chile.

 

Chile has a market of $4.2 billion in pharmaceuticals last year.

 

In addition, the CENABAST's public procurement purchases amounted to $1 billion, of which pharmaceutical products accounted for 84.2%, the highest at $ 850 million.

 

The government's medical spending is expected to continue to increase due to the increased incidence of chronic diseases in Chile, the aging population, and the expansion of access to healthcare services to improve health care.

 

Chile's major importers of pharmaceuticals are the United States, Germany, France and India, and Korea ranks 28th in the total import market.

 

Korean companies such as Daewoong, Korea United Pharm, Green Cross, Daewon Pharmaceutical, Samjin Pharm, Ildong Pharmaceutical, and Boryung have exported biosimilars, anti-cancer drugs, and pharmaceuticals to Chile.